Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


R&D, transparency key to sustained private label gains

This article was originally published in The Tan Sheet

Executive Summary

Private labelers must innovate and work closely with retailers to survive investments by national brands looking to win back market share, according to a panel convened by the Private Label Manufacturers Association. The panel - including Taro Pharmaceuticals VP of OTC Products Ed Moniz and Perrigo Consumer Healthcare VP of OTC Marketing Ron Schutt - discussed post-recession strategies for private label marketers. Despite the recent success of store brands, retailers are hesitant to commit to private label suppliers for the long term, which could stifle research and development investments by those firms, according to the panel report PLMA released Sept. 1. Additionally, national players are launching value brands and line extensions as direct challenges to private label, the trade group says. PLMA's panel recommends private labelers make their operations more transparent to retail chains, which now require more value-added benefits from their store brand products

You may also be interested in...

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy

Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.

Price Inflation Rebates And The Spectre Of 100% Discounts In Medicare Part D

Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts